Maria Elisa Mancuso Selected Research

Hemophilia A (Haemophilia)

9/2022	Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis.
5/2022	Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022.
1/2022	Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.
1/2022	Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors.
11/2021	Optimising prophylaxis in haemophilia A: The ups and downs of treatment.
11/2021	Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
6/2021	The Role of Physiotherapy in the New Treatment Landscape for Haemophilia.
6/2021	Recombinant factor VIII Fc for the treatment of haemophilia A.
5/2021	Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study.
5/2021	PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Elisa Mancuso Research Topics

Disease

52	Hemophilia A (Haemophilia) 09/2022 - 08/2005
19	Hemorrhage 09/2022 - 08/2005
5	Hemophilia B (Haemophilia B) 02/2022 - 09/2016
4	Infections 01/2020 - 08/2005
3	Chronic Hepatitis C 01/2020 - 10/2006
2	Fibrosis (Cirrhosis) 01/2020 - 10/2006
2	Inflammation (Inflammations) 01/2017 - 07/2016
1	Thrombosis (Thrombus) 09/2022
1	COVID-19 06/2021
1	Lung Injury 06/2021
1	Pneumonia (Pneumonitis) 06/2021
1	Myocardial Infarction 01/2021
1	Joint Diseases (Joint Disease) 01/2021
1	Thrombotic Microangiopathies 01/2021
1	HIV Infections (HIV Infection) 01/2020
1	Liver Diseases (Liver Disease) 01/2020
1	Metrorrhagia (Spotting) 12/2019
1	Hepatitis C 11/2018
1	Osteoporosis 11/2018
1	Glioblastoma (Glioblastoma Multiforme) 09/2017
1	Neoplasms (Cancer) 09/2017
1	Disease Progression 06/2014
1	Vomiting 10/2006
1	Blood-Borne Infections 05/2006
1	Afibrinogenemia (Fibrinogen Deficiency) 05/2006
1	Inherited Blood Coagulation Disorders 05/2006
1	von Willebrand Diseases (von Willebrand's Disease) 04/2006

Drug/Important Bio-Agent (IBA)

27	Factor VIII (Coagulation Factor VIII)IBA 01/2022 - 08/2005
10	Blood Coagulation Factors (Coagulation Factor)IBA 01/2021 - 05/2006
8	emicizumabIBA 01/2021 - 01/2019
6	Factor IX (Coagulation Factor IX)FDA LinkGeneric 02/2022 - 01/2014
6	BAY 94-9027IBA 05/2021 - 09/2019
5	Monoclonal AntibodiesIBA 09/2022 - 12/2019
4	Proteins (Proteins, Gene)FDA Link 02/2022 - 01/2018
4	Antiviral Agents (Antivirals)IBA 01/2020 - 04/2006
3	Hemostatics (Antihemorrhagics)IBA 06/2021 - 05/2006
3	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 11/2020 - 01/2018
2	AlbuminsIBA 02/2022 - 09/2016
2	6-pyruvoyltetrahydropterin synthase (PTPS)IBA 05/2021 - 01/2020
2	A-factor (Streptomyces)IBA 01/2021 - 05/2006
2	CoagulantsIBA 01/2021 - 01/2019
2	InterferonsIBA 01/2020 - 10/2006
2	Recombinant Fusion ProteinsIBA 01/2020 - 09/2016
2	Factor IXa (Coagulation Factor IXa)IBA 12/2019 - 01/2019
2	Thrombin FDA Link 01/2019 - 02/2016
2	nonacog beta pegolIBA 11/2018 - 01/2018
2	Neutralizing AntibodiesIBA 05/2016 - 01/2016
1	lipoprotein-associated coagulation inhibitor (TFPI)IBA 09/2022
1	human F8 protein FDA Link 01/2022
1	simoctocog alfa (Nuwiq)IBA 11/2021
1	Complement System Proteins (Complement)IBA 06/2021
1	recombinant factor VIII N8IBA 01/2021
1	Prothrombin (Factor II)IBA 01/2021
1	3'-(1-butylphosphoryl)adenosineIBA 01/2021
1	Adenosine Monophosphate (AMP)IBA 12/2020
1	BAX 855IBA 11/2020
1	Human Serum Albumin FDA LinkGeneric 01/2020
1	AntibodiesIBA 12/2019
1	Heme (Haem)IBA 05/2019
1	LigandsIBA 01/2019
1	Coenzymes (Enzyme Cofactors)IBA 01/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2017
1	ChemokinesIBA 01/2017
1	CytokinesIBA 01/2017
1	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 07/2016
1	von Willebrand FactorIBA 05/2016
1	IsoantibodiesIBA 05/2016
1	CytosineIBA 03/2016
1	ThymineIBA 03/2016
1	NucleotidesIBA 03/2016
1	Interferon LambdaIBA 06/2014
1	Alanine Transaminase (SGPT)IBA 10/2006
1	Ribavirin (Virazole)FDA LinkGeneric 10/2006
1	Fibrinogen (Factor I)FDA Link 05/2006
1	Detergents (Detergent)IBA 05/2006
1	SolventsIBA 05/2006
1	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 04/2006
1	Transaminases (Aminotransferases)IBA 04/2006

Therapy/Procedure

20	Therapeutics 09/2022 - 04/2006
1	Arthrodesis 11/2018
1	Injections 09/2016
1	Arthroplasty 07/2009
1	Minor Surgical Procedures (Minor Surgery) 05/2006
1	Operative Surgical Procedures 08/2005